Rosuvastatin and Tinnitus
The evidence regarding rosuvastatin causing tinnitus is conflicting, but the FDA drug label does not list tinnitus as a recognized adverse effect, and the most recent high-quality research suggests rosuvastatin may actually improve tinnitus rather than cause it. 1
Can Rosuvastatin Cause Tinnitus?
Tinnitus is not listed as an adverse effect in the FDA-approved rosuvastatin drug label, which comprehensively documents side effects observed in clinical trials. 1 The most common adverse effects reported include headache, nausea, muscle aches, weakness, and constipation—but not tinnitus. 1
Conflicting Research Evidence
The research literature presents contradictory findings:
Evidence suggesting benefit (more recent and specific):
A 2019 prospective study specifically examining rosuvastatin found that rosuvastatin 10 mg and 20 mg significantly decreased tinnitus frequency, duration, severity, and degree of annoyance in hyperlipidemic patients over 6 months. 2 This study also showed improved hearing thresholds at 6000 Hz and better speech discrimination with rosuvastatin.
A 2024 Mendelian randomization study (Level 3 evidence) found that genetically predicted use of rosuvastatin showed potential for treating sensorineural hearing loss, though the authors noted further investigation is needed. 3
Evidence suggesting harm (less specific to rosuvastatin):
A 2025 retrospective database study using the All of Us database found an association between statin use generally and both hearing loss and tinnitus. 4 However, this study examined all statins together and found fluvastatin had the weakest association with tinnitus (OR = 1.02, P = .68), while simvastatin had the strongest. Rosuvastatin was not specifically analyzed separately.
A 2024 FAERS database analysis identified drug-related tinnitus reports but did not specifically highlight rosuvastatin as a major culprit. 5
Clinical Interpretation
The weight of evidence favors that rosuvastatin does not cause tinnitus and may actually improve it in patients with hyperlipidemia. The FDA label's absence of tinnitus as a documented adverse effect, combined with the 2019 prospective study showing improvement in tinnitus with rosuvastatin specifically, outweighs the less specific database studies that examined statins as a class.
Recommended Management Approach
If a patient on rosuvastatin develops tinnitus:
Do not automatically attribute it to rosuvastatin—investigate other causes first (noise exposure, age-related hearing loss, other medications, ear pathology, hypertension, diabetes). 2
Review the patient's lipid control—the tinnitus may actually be related to undertreated hyperlipidemia rather than the statin itself. 2
If tinnitus persists and other causes are ruled out, consider the statin intolerance algorithm from Canadian guidelines [@1-4@]:
- Continue rosuvastatin if cardiovascular benefit outweighs the symptom burden
- If switching is necessary, try a different statin (the evidence suggests individual statins may have different effects)
- Consider intermittent dosing (rosuvastatin 5 mg 2-3 times weekly still provides meaningful LDL-C reduction of 32%) 6
- Use non-statin adjuncts if needed to achieve lipid targets
Do not discontinue statin therapy without attempting rechallenge or alternative strategies—92% of patients who experienced statin-related events and were rechallenged remained on a statin at 12 months. 6
Important Caveats
- The 2019 study showing benefit was relatively small and requires confirmation in larger trials
- Database studies showing associations cannot prove causation and may reflect confounding by indication (sicker patients get statins)
- Individual patient responses vary—some patients may genuinely experience tinnitus with any statin
The cardiovascular mortality benefit of statins in appropriate patients far outweighs the uncertain and likely minimal risk of tinnitus. Prioritize maintaining statin therapy for cardiovascular protection while investigating and managing tinnitus through other means.